These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 34449935)

  • 21. A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.
    Proudman D; Nellesen D; Gupta D; Adib D; Yang J; Mamlouk K
    Adv Ther; 2022 Apr; 39(4):1678-1696. PubMed ID: 35157216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TARC, a CC chemokine, is frequently expressed in classic Hodgkin's lymphoma but not in NLP Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and most cases of anaplastic large cell lymphoma.
    Peh SC; Kim LH; Poppema S
    Am J Surg Pathol; 2001 Jul; 25(7):925-9. PubMed ID: 11420464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features.
    Sarkozy C; Morschhauser F; Dubois S; Molina T; Michot JM; Cullières-Dartigues P; Suttle B; Karlin L; Le Gouill S; Picquenot JM; Dubois R; Tilly H; Herbaux C; Jardin F; Salles G; Ribrag V
    Clin Cancer Res; 2020 Jul; 26(13):3145-3153. PubMed ID: 32122924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives.
    Simeone N; Frezza AM; Zaffaroni N; Stacchiotti S
    Future Oncol; 2021 Apr; 17(10):1253-1263. PubMed ID: 33289402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy.
    Kazansky Y; Cameron D; Mueller HS; Demarest P; Zaffaroni N; Arrighetti N; Zuco V; Kuwahara Y; Somwar R; Ladanyi M; Qu R; de Stanchina E; Dela Cruz FS; Kung AL; Gounder MM; Kentsis A
    Cancer Discov; 2024 Jun; 14(6):965-981. PubMed ID: 38315003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of novel pyridone-benzamide derivatives possessing a 1-methyl-2-benzimidazolinone moiety as potent EZH2 inhibitors for the treatment of B-cell lymphomas.
    Wu D; Zeng X; Zhao Y; Qin M; Gong P
    Bioorg Med Chem; 2024 May; 105():117725. PubMed ID: 38640588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas.
    Knutson SK; Warholic NM; Johnston LD; Klaus CR; Wigle TJ; Iwanowicz D; Littlefield BA; Porter-Scott M; Smith JJ; Moyer MP; Copeland RA; Pollock RM; Kuntz KW; Raimondi A; Keilhack H
    PLoS One; 2014; 9(12):e111840. PubMed ID: 25493630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).
    Dockerill M; Gregson C; O' Donovan DH
    Expert Opin Ther Pat; 2021 Feb; 31(2):119-135. PubMed ID: 33103538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isothiocyanates Potentiate Tazemetostat-Induced Apoptosis by Modulating the Expression of Apoptotic Genes, Members of Polycomb Repressive Complex 2, and Levels of Tri-Methylating Lysine 27 at Histone 3 in Human Malignant Melanoma Cells.
    Anestopoulos I; Paraskevaidis I; Kyriakou S; Giova LE; Trafalis DT; Botaitis S; Franco R; Pappa A; Panayiotidis MI
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EZH2: a novel target for cancer treatment.
    Duan R; Du W; Guo W
    J Hematol Oncol; 2020 Jul; 13(1):104. PubMed ID: 32723346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.
    Morschhauser F; Tilly H; Chaidos A; McKay P; Phillips T; Assouline S; Batlevi CL; Campbell P; Ribrag V; Damaj GL; Dickinson M; Jurczak W; Kazmierczak M; Opat S; Radford J; Schmitt A; Yang J; Whalen J; Agarwal S; Adib D; Salles G
    Lancet Oncol; 2020 Nov; 21(11):1433-1442. PubMed ID: 33035457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EZH2-mediated inhibition of KLF14 expression promotes HSCs activation and liver fibrosis by downregulating PPARγ.
    Du Z; Liu M; Wang Z; Lin Z; Feng Y; Tian D; Xia L
    Cell Prolif; 2021 Jul; 54(7):e13072. PubMed ID: 34031939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AP-2α-Mediated Activation of E2F and EZH2 Drives Melanoma Metastasis.
    White JR; Thompson DT; Koch KE; Kiriazov BS; Beck AC; van der Heide DM; Grimm BG; Kulak MV; Weigel RJ
    Cancer Res; 2021 Sep; 81(17):4455-4470. PubMed ID: 34210752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
    Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
    Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The biological environment of Hodgkin's lymphoma and the role of the chemokine CCL17/TARC.
    Hnátková M; Mociková H; Trnený M; Zivný J
    Prague Med Rep; 2009; 110(1):35-41. PubMed ID: 19591376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. When to Use Targeted Therapy for the Treatment of Follicular Lymphoma.
    Nastoupil LJ
    Curr Hematol Malig Rep; 2021 Feb; 16(1):45-51. PubMed ID: 33797691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tazemetostat for the treatment of multiple types of hematological malignancies and solid tumors.
    Marsh S; Jimeno A
    Drugs Today (Barc); 2020 Jun; 56(6):377-387. PubMed ID: 32525136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma.
    Tong KI; Yoon S; Isaev K; Bakhtiari M; Lackraj T; He MY; Joynt J; Silva A; Xu MC; Privé GG; He HH; Tiedemann RE; Chavez EA; Chong LC; Boyle M; Scott DW; Steidl C; Kridel R
    Clin Cancer Res; 2021 Oct; 27(19):5401-5414. PubMed ID: 34168051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of EZH2 Reduces Aging-Related Decline in Interstitial Cells of Cajal of the Mouse Stomach.
    Taheri N; Choi EL; Nguyen VTT; Zhang Y; Huynh NM; Kellogg TA; van Wijnen AJ; Ordog T; Hayashi Y
    Cell Mol Gastroenterol Hepatol; 2024; 18(4):101376. PubMed ID: 38969206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tazemetostat: First Approval.
    Hoy SM
    Drugs; 2020 Apr; 80(5):513-521. PubMed ID: 32166598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.